Bristol-Myers Squibb Company (BMY) is an interesting player in the Healthcare space, with a focus on Drug Manufacturers – Major. The stock has been active on the tape, currently trading at $66.68, down from yesterday’s close by -1.14%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.Fundamental Analysis
Bristol-Myers Squibb Company (BMY) currently trades with a market capitalization of $109.09 Billion. That value represents a market adjusting for revenues that have been growing by 3.93 % on a quarterly year/year basis as of the company’s last quarterly report.
You can get a sense of how sustainable that is by a levered free cash flow of $4.22 Billion over the past twelve months. Generally speaking, earnings are expected to fall in coming quarters. Analysts are forecasting earnings of $0.84 on a per share basis this quarter. Perhaps, that suggests something about why 0.36% of the outstanding share supply is held by institutional investors.
No analysis is ever complete without a thorough survey of a stock’s technical behavior. Looking at the stock’s movement on the chart, Bristol-Myers Squibb Company recorded a 52-week high of $70.05. It is now trading 3.37% off that level. The stock is trading $64.19 its 50-day moving average by -2.49%. The stock carved out a 52-week low down at $51.56.
In recent action, Bristol-Myers Squibb Company (BMY) has made a move of +5.57% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 16.68, and it’s gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 0.84% with $1.63 Billion sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of BMY.